concentrations. Autoimmune thyroid disease was diagnosed when at least 1 antithyroid autoantibody titer was elevated (antithyroglobulin antibodies, anti-TPO antibodies) along with the presence of sonographic signs of chronic inflammation on a thyroid ultrasound.
The exclusion criteria were any comorbidities or use of medications that could interfere with the absorption or assessment of thyroid hormones or TSH (ie, cancer, insufficiency of the pituitary gland, heart, liver, and kidney diseases; medications: hormonal replacement therapy or oral contraceptives, proton pump inhibitors or histamine H 2 -receptor antagonists, metformin, steroids, liothyronine, calcium, and iron preparations). TSH, free thyroxine (FT 4 ), and FT 3 levels were measured in every patient before and 4 to 6 months after increasing the dose of LT 4 . Blood samples were drawn in the morning, before the ingestion of the patient's usual LT 4 medication. The QoL was assessed with the Polish version of the thyroidspecific questionnaire, ThyPRO. ThyPROpl was prepared according to standard methodology for translation of patient-reported outcomes.
6 Patients were asked to answer ThyPROpl before the dose of LT 4 was increased and 4 to 6 months after.
TSH, FT 4 , and FT 3 levels were measured using the electrochemiluminescence technique (Roche Diagnostics GmbH, Mannheim, Germany; reference ranges: TSH, 0.27-4.2 mU/l; FT 4 , 11.5-21.0 pmol/l; FT 3 , 3.9-6.7 pmol/l). Anti-TPO antibodies were measured by a radioimmunoassay (Roche Diagnostics GmbH; reference range <34 IU/ml).
Introduction An association between thyroid insufficiency and disturbances of mood and cognition has been observed in clinical studies.
1 Moreover, even subclinical hypothyroidism has been shown to affect psychological well-being, while supplementation of levothyroxine (LT 4 )-to improve patients' quality of life (QoL). In everyday clinical practice, we often observe patients who still present with symptoms indicating thyroid insufficiency (suggesting an inadequate dose of LT 4 ), despite having normal thyroid-stimulating hormone (TSH) levels.
In a community-based study, Saravanan et al 2 proved that the QoL in euthyroid patients treated with LT 4 was lower than that in the control group. Some authors have suggested that thyroid autoimmunity may influence patients' psychological well-being independently of thyroid function.
3
In addition, antithyroperoxidase (anti-TPO) antibodies may contribute to psychological morbidity in euthyroid individuals. On the other hand, we should consider the possibility that free thyroid hormones are directly responsible for mood.
4
In view of recent studies showing that LT 4 therapy is associated with lower free triiodothyronine (FT 3 ) concentrations despite lower TSH levels, we may hypothesize that TSH monitoring does not fully reflect restoration of thyroid function in those patients. 5 The aim of our study was to examine whether an increase in the dose of LT 4 , resulting in higher FT 3 levels in patients who initially presented with hypothyroid symptoms despite having normal TSH, helps relieve their symptoms.
Patients and methods
This was a prospective case-control study. From March 2014 to September 2014, consecutive patients with hypothyroidism during a course of benign thyroid disease were enrolled to the study. All patients complained of symptoms characteristic of thyroid hormone insufficiency, despite having adequate TSH There were significant differences in FT 3 levels (P <0.0001; Wilcoxon test), FT 4 levels (P <0.0001; paired t test), and TSH levels (P <0.0001; paired t test) before and after the increase of the LT 4 dose.
Four to six months after the increase in the LT 4 dose, scores improved significantly in hypothyroid symptoms, anxiety, cognitive complaints, tiredness, depressive symptoms, emotional susceptibility, impaired daily life, impaired social life, impaired sex life, cosmetic complaints, and goiter symptoms (TABLE 1) .
The FT 3 concentration before and after the increase of LT 4 dose was inversely associated with several QoL outcomes (Spearman's correlation coefficient test): anxiety (r = -0.3; P = 0.02), depressivity (r = -0.3; P = 0.03), emotional susceptibility (r = -0.5; P = 0.0001), goiter symptoms (r = -0.3; P = 0.01), and tiredness (r = -0.4; P = 0.001). There was also a tendency for the association between the FT 3 level and impaired sex life (r = -0.3; P = 0.055). The FT 4 concentration was significantly associated with depressivity (r = -0.3; P = 0.02) and cosmetic complaints (r = -0.3; P = 0.006). The TSH level significantly correlated with depressivity (r = 0.25; P = 0.045) and cosmetic complaints (r = 0.3; P = 0.002).
Discussion
There have been numerous studies that investigated the effect of thyroid dysfunction on patients' QoL, but only a few addressed the question about the possible effect of serum concentrations of free thyroid hormones on the well-being of euthyroid patients. We hypothesized that in "biochemically euthyroid" patients on LT 4 therapy reporting symptoms of thyroid gland insufficiency, an increase of LT 4 dose may improve their symptoms. To detect the differences, we used the ThyPROpl questionnaire, which is a comprehensive instrument specifically reflecting parameters were performed with the Wilcoxon test. The strength of the relationship between analyzed parameters was measured with the Spearman's correlation coefficient test. Results were presented as medians and interquartile ranges (IQRs). All tests were performed 2-tailed and were considered as significant at a P value of less than 0.05.
Results
A total of 423 patients underwent screening, of whom 46 reported complaints indicating thyroid insufficiency. Owing to the exclusion criteria, 37 patients were finally enrolled in the study, and 33 female patients were able to complete the study (median age, 51 years [IQR, 37.8-64 years]; age range, 18-75 years). The study flow chart is presented in Supplementary material online. At baseline, the median levels of TSH, FT 4 , and FT 3 were 1.93 μU/ml (IQR, 1.1-2.29 μU/ml), 16.52 pmol/l (IQR, 15.58-18.35 pmol/l), 3.94 pmol/l (IQR, 3.74-4.29 pmol/l), respectively. These serum levels were achieved by the daily administration of 79 ±38 μg of LT 4 . Eighteen women had Hashimoto thyroiditis, 11 were thyroidectomized, and 8 had been treated with radioiodine (median thyroid volumes were 9.4 ml [IQR, 7.2-12.6 ml]; 1.26 ml [IQR, 0.7-3.6 ml]; and 5.1 ml [IQR, 2.8-6.0 ml], respectively). The median anti-TPO antibody titer of Hashimoto patients was 156 IU/ml (IQR, 89-186 IU/ml).
The daily dose of LT 4 was increased to 110 ±40 μg (P <0.0001; paired t test). The median TSH level after increasing the dose of LT 4 was 0.50 µU/ml (IQR, 0.24-1.04 µU/ml); of FT 4 , 19.76 pmol/l (IQR, 18.12-20.88 pmol/l); and of FT 3 , 4.67 pmol/l (IQR, 4.38-5.11 pmol/l). After the dose increase, 10 of 33 patients had TSH levels below the reference range (0.1-0.26 mU/l), but their TSH levels were not completely suppressed. reflecting an inadequate dose of LT 4 . Furthermore, in severe cases, low FT 3 concentrations might be explained by euthyroid sick syndrome. Therefore, in our opinion, dose escalation in patients with cardiovascular diseases is not plausible and reasonable. It is still debatable whether low serum TSH concentrations in patients treated with LT 4 is associated with increased risk of cardiovascular disease or arrhythmias. In a population-based study, LT 4 therapy was safe in patients with low TSH levels (defined as 0.04-0.4 mU/l). 10 Our results might be interpreted in a broader context of the role of TSH measurement in the monitoring of patients on LT 4 therapy. Recently, Hoermann et al 5,11 proved that both TSH and FT 3 levels are lower in LT 4 -treated patients, suggesting that the reference range for TSH in this group of patients should be revised. Our findings provide some support for those postulates, and we suggest that the levels of free thyroid hormones should also be measured to assess the adequacy of replacement therapy, particularly in symptomatic patients. We have also previously reported the beneficial effect of such an approach among LT 4 -treated women with Hashimoto thyroiditis diagnosed with idiopathic infertility. 12 Limitation of the study The main limitation of our study is the sample size. However, it was a prospective study among patients without any relevant comorbidities, and we used a validated disease-specific questionnaire to measure changes in the QoL.
Supplementary material online Supplementary material online is available with the online version of the manuscript at www.pamw.pl.
all aspects of life affected by benign thyroid disorders. It was originally developed and validated by Torquil Watt in Denmark and has been translated into many languages.
Initially, patients' scores indicated that Tiredness and Emotional Susceptibility were the most affected domains, and the Impaired Social Life domain was the least affected. Our results suggested that the QoL of patients on LT 4 therapy is associated with FT 3 and FT 4 levels, and an increase in the concentrations of free thyroid hormones, particularly FT 3 , leads to an improvement of the symptoms. Saravanan et al 7 observed the association of FT 4 levels with the patients' QoL measured by the General Health Questionnaire and Thyroid Symptoms Questionnaire (TSQ), but did not find any relationship with FT 3 . It should be emphasized that we were able to detect changes in the patients' QoL because we used a sensitive, reliable, and validated questionnaire, ThyPRO, which covers a broad spectrum of patients' complaints caused by benign thyroid diseases. The TSQ used by Saravanan et al 7 has not been validated, and this may explain why the authors were not able to detect the effect of FT 3 on the QoL.
FT 3 is the active form of thyroid hormones; it is transported across the cell membrane in the central nervous system (CNS) by carriers: monocarboxylate transporter (MCT8) and organic aniontransporting polypeptide (OATP1C1). 8 MCT8 is mainly responsible for highly specific transport of T 3 into the intracellular compartment, regulating the bioavailability of T 3 in the CNS. The intracellular T 3 availability is also determined by the action of deiodinases, including D 3 , which predominantly prevents excessive neuronal T 3 concentrations. D 2 produces T 3 from T 4 , and T 4 is probably mainly transported by OATP1C1. T 3 binds to nuclear receptors (TRα and TRβ) and controls the expression of target genes. High expression of TRα and TRβ was found in brain regions responsible for mood and cognition (amygdala and hippocampus). 4 The exact mechanism of how thyroid hormones influence brain functions is still being investigated, but undoubtedly, an imbalance of thyroid hormones resulting from an inadequate dose of LT 4 has an adverse effect on patients' mood, cognition, and well-being. Interestingly, despite the increase in the dose of LT 4 , no patients experienced symptoms of overdose, and the high tolerability of such therapy was reported by patients on the hyperthyroid scale.
In our study, the LT 4 dose escalation did not lead to a further increase in FT 3 concentrations in 1 patient. Recently, Midgley et al 9 also described this paradoxical effect, explaining that a higher LT 4 dose might inhibit the conversion efficiency in some patients. Identifying those patients is important in clinical practice, since they might be candidates for combined T 3 /T 4 therapy.
Patients with concomitant coronary heart disease or arrhythmias are more likely to have several complaints. However, these complaints might be related to cardiovascular disease, rather than
